Dysregulation of serotonergic neurotransmission in Parkinson disease: A key duet
European Journal of Pharmacology,
Год журнала:
2025,
Номер
unknown, С. 177419 - 177419
Опубликована: Фев. 1, 2025
Язык: Английский
Unravelling the Proteinopathic Engagement of α-Synuclein, Tau, and Amyloid Beta in Parkinson’s Disease: Mitochondrial Collapse as a Pivotal Driver of Neurodegeneration
Neurochemical Research,
Год журнала:
2025,
Номер
50(3)
Опубликована: Апрель 16, 2025
Язык: Английский
Clinical study to investigate the adjuvant role of Pentoxifylline in patients with Parkinson's disease: A randomized controlled study
International Immunopharmacology,
Год журнала:
2025,
Номер
156, С. 114689 - 114689
Опубликована: Апрель 19, 2025
Язык: Английский
Cyclin‐dependent kinase 5 (CDK5) inhibitors in Parkinson disease
Journal of Cellular and Molecular Medicine,
Год журнала:
2024,
Номер
28(11)
Опубликована: Июнь 1, 2024
Abstract
Cyclin‐dependent
kinase
5
(Cdk5)
is
a
protein
expressed
in
postmitotic
neurons
the
central
nervous
system
(CNS).
Cdk5
activated
by
p35
and
p39
which
are
neuron
regulatory
subunits.
Cdk5/p35
complex
calpain
protease
to
form
has
neuroprotective
effect
regulating
synaptic
plasticity
memory
functions.
However,
exaggerated
implicated
different
types
of
neurodegenerative
diseases
including
Parkinson
disease
(PD).
Therefore,
modulation
signalling
may
mitigate
PD
neuropathology.
aim
present
review
was
discuss
critical
role
pathogenesis
PD,
how
inhibitors
effectual
management
PD.
In
conclusion,
overactivated
involved
development
neurodegeneration,
Cdk5/calpain
such
as
statins,
metformin,
fenofibrates
rosiglitazone
can
attenuate
progression
Язык: Английский
Industrializing yeast as a drug repurposing platform for inherited metabolic diseases
bioRxiv (Cold Spring Harbor Laboratory),
Год журнала:
2024,
Номер
unknown
Опубликована: Авг. 26, 2024
Summary
The
development
of
therapies
for
rare
diseases,
particularly
inherited
metabolic
disorders
(IMDs),
faces
significant
challenges
due
to
the
high
cost
and
lengthy
timelines
involved.
This
study
presents
a
yeast-based
platform
drug
repurposing
that
capitalizes
on
remarkable
similarity
between
yeast
human
cellular
pathways.
enables
rapid,
cost-effective
screening
potential
therapeutic
compounds
offering
quick
turnaround
compared
traditional
processes.
Utilizing
TargetMol
library
comprising
∼50%
nutraceuticals,
our
pipeline
accelerates
translation
promising
hits
into
patient
observational
studies
in
as
little
6
months.
We
demonstrate
efficacy
this
through
three
case
context
IMDs,
showcasing
its
uncover
novel
treatments
reduce
time
expense
associated
with
bringing
patients
diseases.
Язык: Английский